Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project

Rodolfo Hurle, Massimo Lazzeri, Elena Vanni, Elena Vanni, Giovanni Lughezzani, Paolo Casale, Alberto Saita, Emanuela Morenghi, Emanuela Morenghi, Giovanni Forni, Pasquale Cardone, Giuliana Lista, Piergiuseppe Colombo, Roberto Peschechera, Luisa Pasini, Silvia Zandegiacomo, Alessio Benetti, Davide Maffei, Ivano Vavassori, Giorgio GuazzoniNicolò Maria Buffi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

© 2018 American Urological Association Education and Research, Inc. Purpose We investigated predictive factors of failure and performed a resource consumption analysis in patients who underwent active surveillance for nonmuscle invasive bladder cancer. Materials and Methods This prospective observational study monitored patients with a history of pathologically confirmed stage pTa (grade 1-2) or pT1a (grade 2) nonmuscle invasive bladder cancer, and recurrent small size and number of tumors without hematuria and positive urine cytology. The primary end point was the failure rate of active surveillance. Assessment of failure predictive variables and per year direct hospital resource consumption analysis were secondary outcomes. Descriptive statistical analysis and Cox regression with univariable and multivariable analysis were done. Results Of 625 patients with nonmuscle invasive bladder cancer 122 with a total of 146 active surveillance events were included in the protocol. Of the events 59 (40.4%) were deemed to require treatment after entering active surveillance. Median time on active surveillance was 11 months (IQR 5–26). Currently 76 patients (62.3%) remain under observation. On univariable analysis only time from the first transurethral resection to the start of active surveillance seemed to be inversely associated with recurrence-free survival (HR 0.99, 95% CI 0.98–1.00, p = 0.027). Multivariable analysis also revealed an association with age at active surveillance start (HR 0.97, 95% CI 0.94–1.00, p = 0.031) and the size of the lesion at the first transurethral resection (HR 1.55, 95% CI 1.06–2.27, p = 0.025). The average specific annual resource consumption savings for each avoided transurethral bladder tumor resection was €1,378 for each intervention avoided. Conclusions Active surveillance might be a reasonable clinical and cost-effective strategy in patients who present with small, low grade pTa/pT1a recurrent papillary bladder tumors.
Original languageEnglish
Pages (from-to)401-406
Number of pages6
JournalJournal of Urology
Volume199
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Urinary Bladder Neoplasms
Hematuria
Observational Studies
Cell Biology
Regression Analysis
Observation
Urine
Prospective Studies
Education
Costs and Cost Analysis
Recurrence
Survival
Research
Neoplasms
Therapeutics

Keywords

  • cost-benefit analysis
  • neoplasm invasiveness
  • risk
  • urinary bladder neoplasms
  • watchful waiting

Cite this

Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. / Hurle, Rodolfo; Lazzeri, Massimo; Vanni, Elena; Vanni, Elena; Lughezzani, Giovanni; Casale, Paolo; Saita, Alberto; Morenghi, Emanuela; Morenghi, Emanuela; Forni, Giovanni; Cardone, Pasquale; Lista, Giuliana; Colombo, Piergiuseppe; Peschechera, Roberto; Pasini, Luisa; Zandegiacomo, Silvia; Benetti, Alessio; Maffei, Davide; Vavassori, Ivano; Guazzoni, Giorgio; Buffi, Nicolò Maria.

In: Journal of Urology, Vol. 199, No. 2, 01.02.2018, p. 401-406.

Research output: Contribution to journalArticle

@article{ec3d98e702524c2f9d46df325e7de40e,
title = "Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project",
abstract = "{\circledC} 2018 American Urological Association Education and Research, Inc. Purpose We investigated predictive factors of failure and performed a resource consumption analysis in patients who underwent active surveillance for nonmuscle invasive bladder cancer. Materials and Methods This prospective observational study monitored patients with a history of pathologically confirmed stage pTa (grade 1-2) or pT1a (grade 2) nonmuscle invasive bladder cancer, and recurrent small size and number of tumors without hematuria and positive urine cytology. The primary end point was the failure rate of active surveillance. Assessment of failure predictive variables and per year direct hospital resource consumption analysis were secondary outcomes. Descriptive statistical analysis and Cox regression with univariable and multivariable analysis were done. Results Of 625 patients with nonmuscle invasive bladder cancer 122 with a total of 146 active surveillance events were included in the protocol. Of the events 59 (40.4{\%}) were deemed to require treatment after entering active surveillance. Median time on active surveillance was 11 months (IQR 5–26). Currently 76 patients (62.3{\%}) remain under observation. On univariable analysis only time from the first transurethral resection to the start of active surveillance seemed to be inversely associated with recurrence-free survival (HR 0.99, 95{\%} CI 0.98–1.00, p = 0.027). Multivariable analysis also revealed an association with age at active surveillance start (HR 0.97, 95{\%} CI 0.94–1.00, p = 0.031) and the size of the lesion at the first transurethral resection (HR 1.55, 95{\%} CI 1.06–2.27, p = 0.025). The average specific annual resource consumption savings for each avoided transurethral bladder tumor resection was €1,378 for each intervention avoided. Conclusions Active surveillance might be a reasonable clinical and cost-effective strategy in patients who present with small, low grade pTa/pT1a recurrent papillary bladder tumors.",
keywords = "cost-benefit analysis, neoplasm invasiveness, risk, urinary bladder neoplasms, watchful waiting",
author = "Rodolfo Hurle and Massimo Lazzeri and Elena Vanni and Elena Vanni and Giovanni Lughezzani and Paolo Casale and Alberto Saita and Emanuela Morenghi and Emanuela Morenghi and Giovanni Forni and Pasquale Cardone and Giuliana Lista and Piergiuseppe Colombo and Roberto Peschechera and Luisa Pasini and Silvia Zandegiacomo and Alessio Benetti and Davide Maffei and Ivano Vavassori and Giorgio Guazzoni and Buffi, {Nicol{\`o} Maria}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.juro.2017.08.091",
language = "English",
volume = "199",
pages = "401--406",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project

AU - Hurle, Rodolfo

AU - Lazzeri, Massimo

AU - Vanni, Elena

AU - Vanni, Elena

AU - Lughezzani, Giovanni

AU - Casale, Paolo

AU - Saita, Alberto

AU - Morenghi, Emanuela

AU - Morenghi, Emanuela

AU - Forni, Giovanni

AU - Cardone, Pasquale

AU - Lista, Giuliana

AU - Colombo, Piergiuseppe

AU - Peschechera, Roberto

AU - Pasini, Luisa

AU - Zandegiacomo, Silvia

AU - Benetti, Alessio

AU - Maffei, Davide

AU - Vavassori, Ivano

AU - Guazzoni, Giorgio

AU - Buffi, Nicolò Maria

PY - 2018/2/1

Y1 - 2018/2/1

N2 - © 2018 American Urological Association Education and Research, Inc. Purpose We investigated predictive factors of failure and performed a resource consumption analysis in patients who underwent active surveillance for nonmuscle invasive bladder cancer. Materials and Methods This prospective observational study monitored patients with a history of pathologically confirmed stage pTa (grade 1-2) or pT1a (grade 2) nonmuscle invasive bladder cancer, and recurrent small size and number of tumors without hematuria and positive urine cytology. The primary end point was the failure rate of active surveillance. Assessment of failure predictive variables and per year direct hospital resource consumption analysis were secondary outcomes. Descriptive statistical analysis and Cox regression with univariable and multivariable analysis were done. Results Of 625 patients with nonmuscle invasive bladder cancer 122 with a total of 146 active surveillance events were included in the protocol. Of the events 59 (40.4%) were deemed to require treatment after entering active surveillance. Median time on active surveillance was 11 months (IQR 5–26). Currently 76 patients (62.3%) remain under observation. On univariable analysis only time from the first transurethral resection to the start of active surveillance seemed to be inversely associated with recurrence-free survival (HR 0.99, 95% CI 0.98–1.00, p = 0.027). Multivariable analysis also revealed an association with age at active surveillance start (HR 0.97, 95% CI 0.94–1.00, p = 0.031) and the size of the lesion at the first transurethral resection (HR 1.55, 95% CI 1.06–2.27, p = 0.025). The average specific annual resource consumption savings for each avoided transurethral bladder tumor resection was €1,378 for each intervention avoided. Conclusions Active surveillance might be a reasonable clinical and cost-effective strategy in patients who present with small, low grade pTa/pT1a recurrent papillary bladder tumors.

AB - © 2018 American Urological Association Education and Research, Inc. Purpose We investigated predictive factors of failure and performed a resource consumption analysis in patients who underwent active surveillance for nonmuscle invasive bladder cancer. Materials and Methods This prospective observational study monitored patients with a history of pathologically confirmed stage pTa (grade 1-2) or pT1a (grade 2) nonmuscle invasive bladder cancer, and recurrent small size and number of tumors without hematuria and positive urine cytology. The primary end point was the failure rate of active surveillance. Assessment of failure predictive variables and per year direct hospital resource consumption analysis were secondary outcomes. Descriptive statistical analysis and Cox regression with univariable and multivariable analysis were done. Results Of 625 patients with nonmuscle invasive bladder cancer 122 with a total of 146 active surveillance events were included in the protocol. Of the events 59 (40.4%) were deemed to require treatment after entering active surveillance. Median time on active surveillance was 11 months (IQR 5–26). Currently 76 patients (62.3%) remain under observation. On univariable analysis only time from the first transurethral resection to the start of active surveillance seemed to be inversely associated with recurrence-free survival (HR 0.99, 95% CI 0.98–1.00, p = 0.027). Multivariable analysis also revealed an association with age at active surveillance start (HR 0.97, 95% CI 0.94–1.00, p = 0.031) and the size of the lesion at the first transurethral resection (HR 1.55, 95% CI 1.06–2.27, p = 0.025). The average specific annual resource consumption savings for each avoided transurethral bladder tumor resection was €1,378 for each intervention avoided. Conclusions Active surveillance might be a reasonable clinical and cost-effective strategy in patients who present with small, low grade pTa/pT1a recurrent papillary bladder tumors.

KW - cost-benefit analysis

KW - neoplasm invasiveness

KW - risk

KW - urinary bladder neoplasms

KW - watchful waiting

UR - http://www.scopus.com/inward/record.url?scp=85038906444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038906444&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2017.08.091

DO - 10.1016/j.juro.2017.08.091

M3 - Article

AN - SCOPUS:85038906444

VL - 199

SP - 401

EP - 406

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -